OptiNose Corp (OPTN): Forecast Levels Chart
This daily price chart for OptiNose, Inc. (OPTN) on the GURU.Markets platform captured the value 8.96. The business relies on external contractors for manufacturing and testing, prioritizing promotion. The company is currently scaling sales of XHANCE for the treatment of rhinosinusitis, utilizing automated assembly lines for the precision manufacturing of drug delivery system components.
%20Consensus%20Target&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_OPTN_-_OptiNose-Inc._-_Consensus-Target "OptiNose, Inc. - OPTN Analyst Forecast Prices (period 07/04/2022 - 05/31/2025) | 👁️GURU.Markets👁️")
Analytical breakdowns for Optinose (OPTN)
- current quotes and average value forecast:
- stock exchange capitalization data:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
Aggregate Debt to Equity OptiNose, Inc.|OPTN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital OptiNose Corp|OPTN - Company Aggregate Debts|Debts to Book Capitalization Optinose|OPTN - Company Long-Term Debt|Company Short-Term Loans and Borrowings OptiNose|Quick Liquidity Indicator optinose.com
- earnings and market ratios statistics:
OPTN - Net Profit|Projected Future Earnings OptiNose, Inc.|OPTN - Price to Earnings Ratio|Future Price to Earnings Multiple OptiNose Inc|OPTN - Price/Earnings to Growth Ratio|Company Value to EBITDA Optinose|OPTN - Operating profit before deduction of amortization|Earnings per share for the last four quarters OptiNose|OPTN - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months optinose.com|OPTN - Earnings growth in current year|Expected net earnings per share growth next year OptiNose, Inc.
General company analysis:OPTN optinose.com
The investment attractiveness of OptiNose, Inc. (OPTN) is determined through the discounting of future cash flows, where fundamental value depends on the market share of innovative spray systems. The weighted average target from investment houses aggregates analysts' capitalization expectations, reflecting the impact of patent protection and lengthy regulatory approval timelines for devices on the fair value of the stock.
Competitors of OptiNose, Inc.
HLN - Average Forecast Price|Price Target Chart Kenvue KVUE|VRNA (Verona Pharma PLC) - Forecast Levels Chart|MENS: Consensus Target|Ligand Corp - Analyst Forecast Prices|Amneal Pharmaceuticals (AMRX) - Price Target Chart|Broker Consensus Forecast PRGO|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target Aquestive Corp|SCPH (scPharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Tectonic|Consensus Target TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Fair Value Consensus|Price Target Chart Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Average Forecast Price|EXOZ: Consensus Target|Oramed Pharmaceuticals - Analyst Forecast Prices|ENTX: Analyst Consensus Forecast|MindWalk Holdings, Inc. - Fair Value Consensus|ABVC (ABVC BioPharma Inc) - Analyst Consensus Forecast|Average Forecast Price Cumberland Corp CPIX|Price Target Chart Quantum BioPharma Ltd (QNTM)|FGEN (fibrogen.com) - Fair Value Consensus|Price Target Chart Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings (RANI) - Average Forecast Price|SNYR - Price Target Chart|Forecast Levels Chart RLYB|LEXX (lexariabioscience.com) - Consensus Target|PULM: Analyst Forecast Prices|PTHL (Pheton Holdings Limited) - Analyst Consensus Forecast|Aptorum (APM) - Analyst Median Target|Price Target Chart Lyra Therapeutics, Inc (LYRA)|impactbiomedinc.com - Broker Consensus Forecast|Price Target Chart TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. (YCBD) - Average Forecast Price|PRFX - Price Target Chart|Analyst Median Target Altamira Therapeutics CYTO|LIPO: Analyst Consensus Forecast|Average Forecast Price Pieris Pharma (PIRS)|Consensus Target PROC|PTPI: Fair Value Consensus|Analyst Consensus Forecast QLI|Analyst Median Target Acelyrin Inc.|Price Target Chart TFF Pharma TFFP
